Gleevec Dosage - Articles

Sort by: Newest Most Comments Relevance

Got CML? On Gleevec? LIve in N… by Matthew Z. Patient Expert

Posted Wed 14 Apr 2010 8:06am Got CML? On Gleevec? LIve in NYC/Metro? Wanna be on TV? Email info@nationalcmlsociety.org (subject line: talk show) ASAP Read on »

Staying on Gleevec Seems to Help Gastro Cancer Patients by Medline Plus Posted Tue 21 Sep 2010 4:00pm TUESDAY, Sept. 21 (HealthDay News) -- Continuous treatment with imatinib (Gleevec) is recommended for patients with advanced gastrointestinal cancer, a new study suggests. The study included 50 patients with advanced gastrointestinal stromal tumors (GIST) who'd been receiving Gleevec for three years and had no disease progression. The patients were Read on »

Gleevec for Nephrogenic Systemic Fibrosis? by Matt S. Posted Mon 04 Aug 2008 12:00am , and photopheresis. In addition, a group headed by Rheumatologist Jonathan Kay at Massachusetts General Hospital is initiating a clinical trial using imatinib mesylate (Gleevec) to treat NSF based on some positive responses in a few patients. Gleevec was initially designed to inhibit the tyrosine kinase activity of the bcr-abl gene fusion product which Read on »

Some With Once-Deadly Leukemia Can Take a Break From Gleevec by HealthFinder Posted Tue 19 Oct 2010 10:00am TUESDAY, Oct. 19 (HealthDay News) -- A small group of people with chronic myeloid leukemia (CML) who decided to stop taking the cancer drug Gleevec (imatinib) have remained cancer...." Gleevec -- a highly targeted member of a class of drugs called protein-tyrosine kinase inhibitors -- was first approved by the U.S. Food and Drug Administration for use against CML Read on »

Gleevec Cancer Drug Reported To Work In Alzheimer’s disease also working in Niemann Pick Type C mouse by Chris H. Posted Thu 02 Sep 2010 7:28am in brain cells, has found out that the cancer drug Gleevec, is a new potential drug target for Alzheimer’s disease and block gamma secretase activating protein. Rudolph Tanzi and Paul Aisen are quoted in the article. I think they would all be very interested to know that Gleevec is also working in Niemann Pick Type C mice and kids afflicted Read on »

Some with Once-Deadly Leukemia Can Take a Break from Gleevec by Medline Plus Posted Tue 19 Oct 2010 4:00pm , Oct. 19 (HealthDay News) -- A small group of people with chronic myeloid leukemia (CML) who decided to stop taking the cancer drug Gleevec (imatinib) have remained cancer-free... expert, Dr. John Cole, chairman of the department of hematology/oncology at the Ochsner Clinic Foundation in New Orleans. "We've simply never used the 'cure' word." Gleevec Read on »

Gleevec for graft versus host disease by Mark Levin Posted Thu 17 Dec 2009 8:51am with other immunosuppressants. Despite these prophylactic therapies, GVHD still develops in 30%-80% of patients. One of the newer potentially promising agents is Gleevec. It is especially attractive for patients transplaned for CML or Philadelphia chromosome positive ALL, where Gleevec has an anti leukemia effect as well. Magro L, Catteau B, Coiteux V Read on »

Gleevec for systemic mastocytosis by Mark Levin Posted Thu 04 Feb 2010 7:35pm Gleevec is in a clinical study: Therapy of HESPVAtypical CML or CMMLand Mastocytosis With Imatinib MesylateNCT00038675. The goal of this clinical research study is to see...) or CMML with PDGF-R fusion genesor mastocytosis. There is significant supporting evidence. Gleevec may be useful in those types of systemic mastocytosis (systemic mast cell Read on »

Gleevec – A drug for Scleroderma by Lauren Posted Mon 19 Oct 2009 12:00am The drug Gleevec has been on my radar since last year when a doctor had mentioned it was being used in trials against Scleroderma. Originally developed for Leukemia... for over a year now and don’t plan to ever again. Why the rant now? Well because turns out he was leading this study on Gleevec for the past couple years at the Hospital Read on »

ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML by Bharat Book Bureau Posted Thu 10 Jun 2010 4:32am HTML clipboardASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML At this year's American Society of Hematology meeting, researchers presented results from a Phase III study comparing Tasigna and Gleevec in newly diagnosed chronic myeloid leukemia. While Tasigna's efficacy is impressive, it is unlikely Read on »